Seroatlas · Human Serome Atlas

CST7

Cystatin-F

Also known as: CYTF_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O76096
Gene: CST7
Ensembl: ENSG00000077984
Chromosome: 20
Canonical length: 145 aa
Protein class: Plasma proteins, Predicted secreted proteins
Secretome location: Secreted to blood
Quaternary structure: Homodimer

OverviewNCBI Gene

The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions. This gene encodes a glycosylated cysteine protease inhibitor with a putative role in immune regulation through inhibition of a unique target in the hematopoietic system. Expression of the protein has been observed in various human cancer cell lines established from malignant tumors. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

145 residues, UniProt reviewed canonical sequence.

>O76096|CST7
     1  MRAAGTLLAF CCLVLSTTGG PSPDTCSQDL NSRVKPGFPK TIKTNDPGVL QAARYSVEKF
    61  NNCTNDMFLF KESRITRALV QIVKGLKYML EVEIGRTTCK KNQHLRLDDC DFQTNHTLKQ
   121  TLSCYSEVWV VPWLQHFEVP VLRCH

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CST7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.41
Highest tissue expression: 1,033 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 1,033 nTPM
spleen: 149 nTPM
lymph node: 69 nTPM
lung: 49 nTPM
appendix: 23 nTPM
urinary bladder: 18 nTPM

Single-cell type

neutrophils: 1,191 nCPM
nk-cells: 596 nCPM
neutrophil progenitors: 306 nCPM
t-cells: 290 nCPM
cdc: 202 nCPM
platelets: 173 nCPM

Immune cell

gdT-cell: 1,290 nTPM
memory CD8 T-cell: 905 nTPM
MAIT T-cell: 722 nTPM
NK-cell: 657 nTPM
total PBMC: 601 nTPM
naive CD8 T-cell: 533 nTPM

Brain region

cerebral cortex: 11 nTPM
cerebellum: 5.3 nTPM
medulla oblongata: 4.5 nTPM
pons: 3.7 nTPM
choroid plexus: 3 nTPM
basal ganglia: 2.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.92
gnomAD pLI: 0
gnomAD missense Z: -0.6
DepMap mean gene effect: 0.14
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CST7 as an antibody target. Whether an autoantibody or antibody against CST7 could matter depends on whether native CST7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CST7 is annotated as secreted, so native CST7 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label CST7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...